Eli Lilly''s Donanemab: Nearing The End Of The Line (NYSE:LLY)
Anti-amyloid drugs only modestly slow down the progression of Alzheimer''s in APOE4 carriers and have no effect on non-carriers. Read what it means for Eli Lilly.
Eli Lilly''s Donanemab: Nearing The End Of The Line (NYSE:LLY)
Anti-amyloid drugs only modestly slow down the progression of Alzheimer''s in APOE4 carriers and have no effect on non-carriers. Read what it means for Eli Lilly.